Seref Coser

Dr. Seref Coser

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in The Prostate
Verified
Journal Article
Closed access
MSMehmet Sevim
Mehmet Sevim
OAOkan Alkis
Okan Alkis
IKİbRahim Güven Kartal
İbRahim Güven Kartal
SCSeref Coser
Seref Coser
HAHüseyin Akman
Hüseyin Akman
BABekir Aras
Bekir Aras

29 May 2025 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
FSFerhat Yakup Suçeken
Ferhat Yakup Suçeken
FSFerhat Yakup Suçeken
Ferhat Yakup Suçeken
SCSeref Coser
Seref Coser
DKDuygu Kurtulus
Duygu Kurtulus
MAMurat Akgül
Murat Akgül
BABekir Aras
Bekir Aras

4 May 2022 in Cureus
Verified
Journal Article
Open access
İKİbrahim Kartal
İbrahim Kartal
HIHalil Ibrahim Ivelik
Halil Ibrahim Ivelik
SCSeref Coser
Seref Coser
HTHazal Tunç
Hazal Tunç
MAMustafa Fuat Açıkalın
Mustafa Fuat Açıkalın
The eosinophilic vacuolated tumor (EVT) of the kidney is a newly identified and pathological emerging entity. In this case report, EVT diagnosed due to a partial nephrectomy performed for a suspicious kidney mass in a 47-year-old patient is presented. A review of the literature and this case indicates that EVT, also called high-grade oncocytoma, does not show clinically aggressive behavior. However, in case of clinical suspicion, tumors with this oncocytic morphology should be treated with nephron-sparing treatment methods, considering that they may be hybrid malignancies.

1 January 2023 in Urology Research and Practice
Verified
Journal Article
Open access
MKMustafa Koray Kırdağ
Mustafa Koray Kırdağ
IOIsa Ozbey
Isa Ozbey
EOEser Ordek
Eser Ordek
AOAhmet Olgun
Ahmet Olgun
MOMehmet Sezai Ogras
Mehmet Sezai Ogras
MÇMehmet Çağlar Çakıcı
Mehmet Çağlar Çakıcı
Objective: The aim of this study is to evaluate current urologic practice regarding the management of priapism in Turkey and compare with international guidelines. Methods: Urologists and urology residents were invited to an online survey consisting of 30 multiple-choice questions on priapism-related clinical practices that were consid- ered most important and relevant to practices by using Google Forms. Results: Total number of responses was 340. Respondents reported that they recorded a detailed patient’s medical history and physical examination findings (n = 340, 100%) and laboratory testing, which includes corporal blood gas analysis (n=323, 95%). Participants announced that they performed Doppler ultrasound for 1/4 cases (n = 106, 31%), but 22% of the participants (n=75) replied that they performed in >75% of cases. Participants (n=311, 91%) responded that the first-line treatment of ischemic priapism is decompression of the corpus cavernosum. Moreover, most respondents (n = 320, 94%) stated that sympathomimetic injection drugs should be applied as the second step. About three-quarters of respondents (n = 247, 73%) indicated adrenaline as their drug of choice. Phosphodiesterase type 5 inhibitors seems to be the most pre- ferred drug for stuttering priapism (n=141, 41%). Participants (n=284, 84%) replied that corpora-glanular shunts should be preferred as the first. A large number of par- ticipants (n = 239, 70%) declared that magnetic resonance imaging can be performed in cases with delayed (>24 hours) priapism to diagnose corporal necrosis. Most of the participants (84%) responded that penile prosthesis should be preferred to shunts in cases with delayed (>48 hours) priapism. Conclusion: It would be appropriate to improve the training offered by professional associations and to give more training time to the management of priapism during residency. Cite this article as: Kalkanli A, Zeki Sönmez S, Guvel M, et al. Management of priapism: Results of a nationwide survey and comparison with international guidelines. Urol Res Pract. 2023;49(4):225-232.

30 April 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
AAAdalet Altunsoy
Adalet Altunsoy
SCSeref Coser
Seref Coser
NKNizamettin Kemirtlek
Nizamettin Kemirtlek
IAIbrahim Can Aykanat
Ibrahim Can Aykanat
MBMelih Balci
Melih Balci
ATAltuğ Tuncel
Altuğ Tuncel
Introduction: This study aims to show the bacteriologic picture of acute prostatitis and bacteremia caused by infective agent after transrectal ultrasound-guided prostate biopsy (TRUSBx) and to determine the resistance rates of the infections in patients undergoing transrectal biopsy and to guide prophylaxis approach before biopsy. Methodology: The retrospective data of 935 patients who underwent TRUSBx between January 2010 to January 2019 were reviewed. Pre-biopsy urine cultures and antimicrobial susceptibility were obtained. Subsequently, patients admitted to the hospital with any complaint after biopsy were examined for severe infection complications. Results: Of the 430 (61.7%) patients who underwent urine culture before the procedure, 45 (10.5%) had growth; 30 (66.7%) of the growing microorganisms were Escherichia coli. Twenty (44.4%) of all Gram-negative agents in pre-biopsy urine culture were susceptible to quinolone. Post TRUSBx bacteremia was present in 18.2%, urinary system infection in 83.6%, and hospitalization in 61.8% of 55 patients who were admitted to the hospital. In the isolated gram-negative microorganisms, fluoroquinolones resistance in urinary system infections was seen in 40% and bacteremia was seen in 70% of the cases. ESBL-producing Gram-negative bacteria were determined in 40% of infections in blood and 38.5% of urinary system infections in the post biopsy period in the current study. Conclusions: These high antibiotic resistance rates suggest that we better review our pre-procedure prophylaxis approaches.

1 January 2023 in Urology Research and Practice
Verified
Journal Article
Open access
OKOzgur Kazan
Ozgur Kazan
NKNilufer Kadioglu
Nilufer Kadioglu
HİHalil İbrahim İvelik
Halil İbrahim İvelik
MSMehmet Sevim
Mehmet Sevim
OAOkan Alkis
Okan Alkis
BABekir Aras
Bekir Aras
Objective: We aimed to evaluate the effect of large and small cribriform morphology on survival following radical prostatectomy. Methods: We included 30 patients who underwent radical prostatectomy with curative intent between 2015 and 2022. Patients with the final pathology of Gleason 7 were included. Patients’ radical prostatectomy specimens were reviewed by an experienced genitourinary pathologist. The diverse growth patterns of Gleason grade 4 were specified as poorly formed/fused glands, cribriform glands, and glomeruloid glands. The cribriform morphology was subdivided into small and large cribriform. Large cribriform growth morphology was defined by its size, which was double that of benign prostate glands. Small and large cribriform glands’ percentages were indicated semiquantitatively. The cribriform morphology subtype present at 50% and higher was defined as the dominant pattern. The effect of histopathological patterns on biochemical recurrence and clinical progression was analyzed. Results: Thirteen patients were small cribriform pattern dominant (group 1), whereas 14 of the patients were large cribriform pattern dominant (group 2). Pathological T, N stages, and surgical margin positivity were similar between groups. Biochemical recurrence and clinical progression rates were significantly higher in group 2. The large cribriform dominant patients had worse 2-year biochemical recurrence-free survival than small cribriform dominant patients (45.5% vs. 66.7%). In the univariate analysis, International Society of Urological Pathology grade, Gleason pattern 4 percentage, large cribriform pattern dominancy, and pT stage were predictors for biochemical recurrence-free survival. International Society of Urological Pathology grade was the only independent predictor for biochemical recurrence-free survival. Conclusion: Large cribriform pattern dominancy is associated with worse biochemical recurrence-free survival in Gleason 7 prostate cancer. Cite this article as: Kazan O, Kadioglu N, Ivelik HI, et al. Distinct adverse clinical outcomes of small and large cribriform patterns on gleason 7 prostate cancer: A preliminary study. Urol Res Pract. 2023;49(5):324-328.